Last updated on October 2018

COM701 in Subjects With Advanced Solid Tumors


Brief description of study

This is a Phase 1 open label sequential dose escalation and cohort expansion study evaluating the safety, tolerability and preliminary clinical activity of COM701 as monotherapy and in combination with a programmed cell death protein 1 (PD-1) inhibitor.

Detailed Study Description

This Phase 1 study evaluates the safety, tolerability, Pharmacokinetics (PK) and preliminary clinical activity of COM701 an inhibitor of poliovirus receptor related immunoglobulin domain containing (PVRIG) as monotherapy and in combination with a PD-1 inhibitor in subjects with advanced solid tumors. Cohort expansion in subjects with the following select tumor types (Non-Small cell lung cancer (NSCLC), Ovarian, Breast (including Triple negative breast cancer (TNBC) and Endometrial cancer) evaluating COM701 monotherapy and in combination with a PD-1 inhibitor will be explored.

Clinical Study Identifier: NCT03667716

Contact Investigators or Research Sites near you

Start Over

COM701 Study Director

The University of Tennessee WEST Cancer Center.
Memphis, TN United States
  Connect »

COM701 Study Director

Sarah Cannon Cancer Institute.
Nashville, TN United States
  Connect »

COM701 Study Director

The START Center for Cancer Care.
San Antonio, TX United States
  Connect »

Recruitment Status: Open


Brief Description Eligibility Contact Research Team


Receive Emails About New Clinical Trials!

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.